Some drugs or indications were withdrawn from the market after reevaluation in post-marketing studies (Wilson et al., 2013), such as the indications that pembrolizumab in second-line treatment of SCLC, nivolumab in second-line treatment of SCLC, nivolumab in second-line treatment of BRAF-positive melanoma, atezolizumab in urothelial cancer and so forth. This evidence concerns the gene BRAF and small cell lung carcinoma.